Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Abbott’s Branded Drug Spin-off Will Boost Profile Of Diversified Device Biz

This article was originally published in The Gray Sheet

Executive Summary

Abbott’s planned spin-off of its branded pharmaceuticals business will raise the profile of its remaining diversified device and diagnostics business while isolating certain long-term risks, including generic drug competition.

You may also be interested in...



Abbott Dumps Generic Drugs Business, Looks For More Device Targets

Mylan will buy Abbott’s non-U.S. developed markets specialty and branded generics business in a stock transaction valued at around $5.3 billion, a deal that will allow it to redomicile in the Netherlands.

Baxter Spins Off Drug Business To Focus On Devices, Anesthesia & Nutrition Products

Kidney dialysis and biosurgery will be two major focus points for a newly refined Baxter after it spins off its biopharmaceuticals business, as planned for mid-2015.

News In Brief

House Majority leader floats device tax repeal as fiscal cliff issue. The U.S. Preventative Services Task Force issued draft recommendations with middling support for hepatitis C screening in the general baby-boomer population. More news.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT030650

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel